News | Radiation Therapy | August 30, 2016

Lumpectomy Plus Radiotherapy Improves Breast Cancer Survival in Community Setting

Study of more than 1,100 breast cancer patients revealed overall survival rates higher than the national average

Vantage Oncology, breast conservation treatment, BCT, lumpectomy radiation therapy, survival rates, clinical study

August 30, 2016 — A recently published study identifies two key research findings regarding breast cancer treatment options. First, breast conservation treatment (BCT), i.e. lumpectomy plus radiation therapy, delivered in a community setting resulted in overall survival rates that are higher than the national average. Second, BCT resulted in overall survival rates that are higher than the national average when compared to other available treatment options.1

The study was published in The Journal of Community and Supportive Oncology.

“We have been treating breast cancer patients in the community setting for several decades and believe we have positively influenced the level of quality care,” said Leslie Botnick, M.D., chief medical officer for Vantage Oncology. “We conducted this study because breast cancer is one of the most commonly treated cancers in radiation oncology. It is very often treated in community settings across the country where many of our affiliated centers have a footprint. We now have demonstration that breast cancer treatment in the community setting has excellent results, with survival rates as good, if not better, than the national average, which includes treatment in the hospital setting.”

“The other bottom line result was that BCT offers excellent survival rates, supporting the idea that breast conservation inclusive of radiation reflects quality care,” said Vantage radiation oncologist May Lin Tao, M.D. “There is a worrisome pendulum swing nowadays away from breast conserving surgery and radiation in situations that are still quite amenable to this approach. These data give excellent reassurance that patients can have superb survival results with this BCT rather than more aggressive surgical options.”

Tao added, “These results are achievable in community settings when care is well-coordinated among specialists who are invested in a high level of care. Often times, women don’t get all of their expected treatment after surgery, such as radiation therapy. We have been fortunate to implement a virtual multidisciplinary care program in our community practices, building on the local expertise of breast surgeons, medical oncologists, radiologists and pathologists.”

The study was funded by Vantage Oncology, and co-authored by Vantage Oncology and Valley Radiotherapy Associates Medical Group (VRA) physicians and clinicians. The purpose of this collaborative research was to determine the rates of positive clinical outcome of BCT in a large urban community and overall survival after conservation therapy, and compare these with national rates.

As part of the study, 1,172 patients diagnosed with T1-2, N0 breast cancer from 1997-2007 were identified in the Providence St. Joseph Medical Center, Burbank, Calif. hospital tumor registry. These results were compared to the rates of BCT and receipt of radiation therapy with a similar population in the SEER [Surveillance, Epidemiology, and End Results] database (N = 232,898) for the same treatment period.

Results showed the rate of breast-conserving surgery (BCS) or lumpectomy was higher in the studied practice compared with the national average (90.9 percent and 66.4 percent, respectively). Similarly, the rate of receipt of radiation after BCS in the studied practice was 93.7 percent, which was also very high as compared to the national average of 74.4 percent. Most importantly, the survival estimates were higher for patients treated with breast conserving surgery plus radiation in the studied practice across all age groups (92.5 percent) compared with the national estimates (82.4 percent).

Botnick noted, “The quality care metrics of rate of breast conservation and the receipt of radiation therapy after BCS were very high in our community setting. That rate has been shown to vary substantially by geographic region in the U.S. rather than by medical indication, with omission rates exceeding 30 percent in some areas2. Furthermore, pooled analyses have shown that omission of radiation after BCS results in higher breast recurrence rates and even a small increase risk in patient mortality.3”

In an effort to progress toward value-based payments from the traditional fee-for-service model, Vantage’s affiliated physician practice in California, VRA, recently partnered with Anthem Blue Cross of California in an agreement to create a single episode-of-care payment for patients with a breast cancer diagnosis requiring radiation therapy treatment.

“We feel one of the reasons we were able to partner with a large payor like Anthem was because we have demonstrated we can provide effective care at a sustainable cost. This is appealing to a payor entity looking to make sure the level of care and patient satisfaction provided to its beneficiaries is high and value-based,” added Botnick.

For more information:


1 Tao ML, Mautner BD, Ray HE, et al. Long-term Community-based Results of Breast Conserving Therapy in Early-stage Breast Cancer. JCSO 2016; 14:249-254.

2J Clin Oncol (2002) 20(21): 4381-93)

3 JNCI J Natl Cancer Inst (2004) 96(2): 115-121

Related Content

Lunit Unveiling AI-Based Mammography Solution at RSNA 2018
News | Mammography | November 15, 2018
Medical artificial intelligence (AI) software company Lunit will be returning to the 104th Radiological Society of...
Breast Density Advocate Nancy M. Cappello Passes Away

Nancy Cappello. Image courtesy of

News | Breast Density | November 15, 2018 | Jeff Zagoudis, Associate Editor
Imaging Technology News extends its condolences to the family, friends and colleagues of Nancy M. Cappello, Ph.D., who...
Life Image and Bringing Artificial Intelligence to Clinical Trial Development
News | Artificial Intelligence | November 15, 2018
Life Image and announced a new strategic partnership that will facilitate the adoption and enhancement of...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
The MOZART Supra Specimen Tomosynthesis System is the latest generation of 3-D imaging for breast cancer surgery.
News | Breast Imaging | November 08, 2018
KUBTEC announced the launch of a new innovation in the treatment of breast cancer. The Mozart Supra Specimen...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...